The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 basket trial of tarlatamab in patients with advanced DLL3-expressing tumors: University of California Lung Cancer Consortium UCCC-01/UCLA L-10.
 
Michael Oh
No Relationships to Disclose
 
Daniel Stefanko
No Relationships to Disclose
 
Gregory Fishbein
No Relationships to Disclose
 
Tianhong Li
Honoraria - Bristol-Myers Squibb US
Consulting or Advisory Role - Bristol Myers Squibb; Janssen
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Chugai Pharma USA (Inst); Duality Biologics (Inst); Genentech (Inst); Jounce Therapeutics (Inst); LabyRx Immuno-Oncology (Inst); Lung Cancer Mutation Consortium (Inst); Merck (Inst); Novartis (Inst); OncoImmune/OncoC4 (Inst); RasCal (Inst); Tempus (Inst); Xilio Therapeutics (Inst)
 
Sandip Patel
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb; Certis Oncology Solutions; Compugen; Illumina; Iovance Biotherapeutics (Inst); Lilly; Lilly; Merck; Nektar; Novartis; Pfizer; Roche/Genentech; Tempus
Speakers' Bureau - Boehringer Ingelheim; Merck
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Fate Therapeutics (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics; Takeda (Inst); Takeda (Inst)
 
Cathleen Park
No Relationships to Disclose
 
Claire Mulvey
Honoraria - OncLive/MJH Life Sciences
Research Funding - RayzeBio
 
Joel Hecht
Stock and Other Ownership Interests - Actym Therapeutics; Rafael Pharmaceuticals; Trumvira
Consulting or Advisory Role - Agenus; Astellas Pharma; BeiGene; Bristol-Myers Squibb/Medarex; Galvanize Therapeutics; MBQ Pharma; Revolution Medicines; Taiho Pharmaceutical; Xilio Therapeutics
Research Funding - A2 Biotherapeutics (Inst); Affini-T Therapeutics (Inst); Agenus (Inst); Amgen (Inst); Bold Therapeutics (Inst); Camurus (Inst); Cardiff Oncology (Inst); CG Pharmaceuticals (Inst); Crinetics Pharmaceuticals (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gritstone Bio (Inst); Janssen Oncology (Inst); Lyell Immunopharma (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neogene Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Regeneron (Inst); Revolution Medicines (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst); Tizona Therapeutics, Inc. (Inst); Xilio Therapeutics (Inst)
 
Edward Garon
Consulting or Advisory Role - ABBVIE/ABBOTT; Arcus Biosciences; ArriVent Biopharma; AstraZeneca; Atreca; Black Diamond Therapeutics; BridgeBio Pharma; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; EMD Serono; Gilead Sciences; Hexagon; Hookipa Biotech; I-Mab; ITeos Therapeutics; LianBio; Lilly; Merck; Merus; Novartis; Nuvalent, Inc.; Pfizer; Regeneron; Sanofi; Seagan; Strata Oncology; Sumitomo Pharma Oncology; Summit Therapeutics; Synthekine
Research Funding - ABL Bio (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); BridgeBio Pharma; Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); EMD Serono (Inst); Genentech (Inst); Gilead Sciences (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Synthekine (Inst); TILT Biotherapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Diagnosistic and therapeutic use of "Motif Neoepitopes" as defined by Cummings et al in Nature Cancer. (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics
Other Relationship - Daiichi Sankyo/Astra Zeneca
 
Amy Cummings
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb/Roche; Daiichi Sankyo/Lilly; Genmab; Merus; OncLive/MJH Life Sciences; Oncohost; Pfizer; Taiho Oncology; Tempus
Research Funding - Amgen Foundation; AstraZeneca (Inst); Genentech (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for bioinformatics approach to identification of motif neoepitopes
 
Aaron Lisberg
Employment - Boston Scientific (I)
Stock and Other Ownership Interests - Boston Scientific (I)
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo Nordics; G1 Therapeutics; Gilead Sciences; IQVIA; Janssen Oncology; Jazz Pharmaceuticals; Leica Biosystems; Lilly; Molecular Axiom; MorphoSys; Novartis; Novocure; Oncocyte; Pfizer; Sanofi; Sanofi/Regeneron
Research Funding - AstraZeneca; Calithera Biosciences; Daiichi Sankyo; Dracen; Duality Biologics; eFFECTOR Therapeutics; WindMIL
Patents, Royalties, Other Intellectual Property - Pending Patents U.S. Provisional Patent Application No. 63/527,899
 
Zev Wainberg
Consulting or Advisory Role - Alligator Bioscience; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; EMD Serono; Ipsen; Janssen Oncology; Lilly; Merck; Merck KGaA; Novartis; Pfizer; PureTech; Revolution Medicines; Seagen
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Lilly; Merck
 
Christine Kivork
No Relationships to Disclose
 
Larissa Ikenouye
No Relationships to Disclose
 
Jonathan Goldman
Consulting or Advisory Role - AbbVie; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Genentech; Summit Biomedical
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lyell Immunopharma (Inst); Pfizer (Inst); Summit Biomedical (Inst)